Naloxone is an opioid antagonist drug that reverses the effects of heroin and other opioid drugs. It does not cause intoxication. It has been used for over 40 years in emergency medicine and anaesthesia [1] . Naloxone is listed on the Australian Pharmaceutical Benefits Scheme as an S4 medication and as such is currently only available by prescription in Australia [2, 3] .
In the mid-1990s calls were made to make naloxone available to opioid (typically heroin) users, their peers and family members to prevent overdose deaths, through 'take-home' naloxone programs [4, 5] . Such programs have now been implemented in many countries including the U.K., the U.S., Canada, Germany, Georgia, Russia, Spain, Norway, Afghanistan, China, Kazakhstan, Tajikistan and Vietnam [6, 7] . Naloxone has been available across the counter in Italy since 1995 [8] and in November 2010 Scotland became the first country internationally to roll out a national Take-home Naloxone program, which was funded for 5 million pounds over 2 years [9] . Accumulating international evidence from these programs shows that the provision of take-home naloxone, with appropriate training, to people who come into contact with people who use opioids (including friends, family, service providers) can lead to successful opioid overdose reversals and that it is a remarkably safe intervention with few, if any, adverse effects [e.g. 9, 10, 11 -19] . In the US alone, as of 2010, there had been over 53,000 kits containing naloxone distributed through 188 programs across 16 US states with 10,171 reported overdose reversals incorporating naloxone administration [20] .
Observational studies have shown declines in overdose mortality subsequent to implementation of take-home naloxone programs in Chicago [14, 21, 22] , New York [23] and San Francisco [24] , but these studies could not control for other potential explanations of these effects. An interrupted time series analysis of 19 geographically distinct cities and towns in Massachusetts found lower opioid related overdose death rates in locations where programs of Overdose Education incorporating Naloxone Distribution (OEND) had been implemented with more than 100 enrolments per 100,000 population (OR =0.54), compared to control communities where no such programs existed, but just failed to find a significant difference between high-dose (> 100 enrolments in OEND per 100,000 population) and low-dose (< 100 enrolments in OEND per 100,000 population) interventions [25] . Importantly, the naloxone programs effects were not evident for other types of acute deaths such as road traffic accidents thus demonstrating specificity of effect to overdose outcomes. Analysis of a recent cost effectiveness model concluded that naloxone administration by trained lay persons is likely to reduce overdose death rates, and is highly cost-effective even under very conservative assumptions [26] . These findings suggest that take-home naloxone is an effective addition to other overdose prevention strategies and the US FDA has recently been considering extending access to naloxone outside of conventional medical settings [27, 28] .
Opioid Overdoses in Australia
In Australia, deaths from heroin and other opioids among people aged between 15 and 54 years peaked at 1116 deaths in 1999, a rate of 10.19 deaths per 100,000 Australians. This rapidly declined to 386 deaths in this age range in 2001, a rate of 3.46 per 100,000 persons [29] . Despite this decline, overdoses involving heroin or other opioids continue to account for most illicit drug related deaths in this country [30] . In 2009, 563 Australians aged between 15 and 54 years died from accidental opioid overdose, a rate of 4.59 deaths per 100,000, up from 3.04 deaths per 100,000 in 2007.Most of these deaths related to the injection of heroin, although deaths from pharmaceutical opioid misuse appear to be rising [29] . Heroin is still the drug of choice among the majority of people surveyed who inject drugs in Australia [31] .
This continued opioid related mortality led to the revival of the idea of take-home naloxone in the Australian academic literature [2, 3] . Although the rates of opioid related mortality remain below those of the heroin 'glut' of the late 1990s [32] , these articles reasoned that it was timely to start to develop take-home naloxone programs in this country, which could be scaled-up over time if and when overdose mortality continued to increase. The aim of this paper is to document recent Australian developments in implementing take-home naloxone, particularly in the ACT, to reflect on key elements of the processes involved in establishing the ACT program, and consider issues associated with future scale up of take-home naloxone in Australia. Central to the success of the developments in the ACT and elsewhere has been co-operative effort of stakeholders across a range of sectors working together toward the shared goal of improving access to take-home naloxone to prevent overdose morbidity and mortality.
As context, the ACT is located in the south east of the country and is an enclave within New South Wales, Australia's most populous state. Canberra, the only city within the ACT, is the seat of the Australian national government. At 2,358 km2 the ACT is the smallest self-governing territory on mainland Australia, and has a population of some 383,000 out of Australia's total population of 23.2 million. [33] The take-home naloxone program in the ACT The accumulating international evidence of program implementation, effectiveness [e.g. 9-11, 13, 14, 17-19] and more recent cost-effectiveness [26, 34] 
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Australia that involved local and international stakeholders [22] . This coincided with supportive coverage about the ACT proposal in the ACT press [39] .
Central to the establishment of the ACT take-home naloxone program was the public support [47] ) and follow-up interviews between 3 and 6 months after the education session and when participant's naloxone is used and they attend for replenishment.
Other take-home naloxone programs in Australia
Elements of the I-ENAACT process have been described in detail elsewhere [46, 48, 49] .
Importantly, the process has welcomed colleagues from other Australian jurisdictions involved in establishing take-home naloxone programs, to share experiences, knowledge, and training and evaluation materials, thereby attempting to minimise duplication of effort. This process, undertaken in a spirit of cooperation and collaboration, provided support for the implementation of the Overdose Prevention Education & Naloxone (OPEN) project [50] There is no doubt that the work underpinning the ACT program establishment and network has harnessed momentum for establishing take-home naloxone in Australia. This has been further facilitated by academic presentations and media interviews by various stakeholders and by endorsements of take-home naloxone interventions by various peak bodies. With regards to the latter, at a national level, programs received support from the Australian Medical Association [51] and the Australian National Council on Drugs in [49] . Endorsement by such esteemed bodies provides governments a level of re-assurance, in addition to the evidence published in the academic literature, that moving forward on take-home naloxone is a successful, defensible public health initiative.
Reflecting on the Australian developments -theoretical aspects
There are a number of theoretical approaches to understanding the policy process and different aspects of this account of the commencement of take-home naloxone programs in Australia reflect these theories. Kingdon's 'multiple-streams' approach [52] explains how some policy ideas survive and others die, depending on the opening and closing of 'policy windows' and the influences of 'policy entrepreneurs', who can bring together three streams of activity: problems, policy and politics. In terms of this theory, the 2009 academic publications [2, 3] , which reminded Australian stakeholders of opioid overdose as an ongoing problem, and the re-invigorated advocacy for the use of take-home naloxone as one additional policy response to that problem, was part of bringing together of Kingdon The 'enlightenment' model [56] explains how research can have an incremental impact on the belief systems of policy makers over time. Indeed the accruing research evidence of successful naloxone program implementation in the US and, to a lesser extent in Europe provided support for local Australian action at a governmental level. Finally, 'Punctuatedequilibrium' theory [57] attempts to explain why political processes typically produce stability and incrementalism, but sometimes also lead to discontinuous, abrupt change. At a macro level this theoretical approach provides insight into the hiatus in development and implementation of peer naloxone programs in Australia due to the end of the 'heroin glut', and the subsequent developments in naloxone programs in the past 12 to 18 months.
Naloxone program rollout and scale-up issues
If take-home naloxone programs in Australia are going to be scaled up to a level where population impacts on rates of opioid overdose related fatalities can be determined, certain challenges will need to be met. These include:
(i) Scheduling and cost. In Australia currently available naloxone products are prescriptiononly medication under Schedule 4. If these products were to be re-scheduled to S3 to make them available across the counter, they would no longer be covered by Pharmaceutical Benefits Scheme (PBS) and the cost per dose is likely to increase significantly. The cost of naloxone is currently listed (exclusive of dispensing fee) as $16.64 per 400 microgram/ml minijet® distributed by UCB Australia. But under the PBS consumers can get up to 5 minijets® for $36.50 or $5.50 on concession. Most naloxone programs in Australia provide a minimum of 2 x minijets® per kit, but the cost of these is currently borne by the program, rather than the recipient which is unlikely be the case if programs were scaled up. It is imperative that cost factors are not a barrier to those of low incomes, and programs that provide to them, getting access to naloxone. However, it may be the case that in future there could be a range of naloxone products available, for example some in an injectable form, others in an intranasal form. Although all products should be available to those of low income at the lowest possible cost, there is no reason why each these products should be identically scheduled or under the same pricing structure.
(ii) Administration to third parties in an overdose emergency. Naloxone programs currently provide naloxone under prescription with the intention that it will be administered to the person whose name is on the prescription. Should the medication be administered to a third person in an emergency situation, this can be covered under Good Samaritan laws that exist across Australian jurisdictions, although coverage is not perfect. For example, in both ACT and NSW [58, 59] such laws exclude persons under the influence of a drug. Despite this, advice provided by government solicitors to authorities in at least one Australian jurisdiction where peer naloxone programs now operate have suggested it would be extremely unlikely that legal action would be pursued against someone trying to save a life with naloxone. [63] . To allow widespread IN use, an application would need to be made to the TGA for a higher concentration naloxone product suitable for that mode of delivery.
(v) Naloxone for service provider administration. There is an obvious case for providing training and naloxone to service providers who are likely to witness overdoses as part of their employment. These include, but are not limited to, peer outreach workers, needle exchange staff, drug treatment workers, staff at shelters and other emergency accommodation services, and indeed, police and other emergency services workers. In Australia, such staff are expressing a need for naloxone training, but they cannot be provided naloxone under the current prescription model. Particularly now that IM injection practice associated with the use of an adrenaline auto-injector [64] has been adopted as part of First AID training courses in this country (I. Jacobs, personal communication, 27/01/2014), a mechanism for supplying naloxone to workers needs to be identified.
(vi) Alliance of drug user groups, clinicians and others. In Australia, as elsewhere, drug user groups have been central to the advocacy for and development of take-home naloxone programs. These programs have also been characterised by drug users, clinicians, public servants, service agencies, peak bodies, researchers and others working together to achieve a common goal. As the expansion of naloxone provision continues, it needs to embrace a variety of forms, depending on the setting. These will range from drug user-led group settings, to one-on-one sessions between client and clinician and everything in between.
Future developments in this area must continue to be characterised by ongoing respectful sharing of specialist knowledge between drug user representatives, clinicians and others, for the full life-saving potential of this intervention to be realised.
Conclusion
In this paper we have argued that the clinical and biological evidence that naloxone can reverse the effects of opioid overdose has been supplemented by evidence that naloxone can be used safely by trained non-medical peers and overdose bystanders (with many thousands of overdose reversals now reported). Further, a growing body of ecological studies of increasing sophistication suggests that take-home naloxone programs save lives and are costeffective. This evidence has supported the careful rollout and evaluation of programs in this country. Importantly, the call has been for take-home naloxone to be implemented in addition to, rather than instead of, other existing evidence based strategies for reducing the risk of opioid overdose, most importantly increasing access to opioid substitution treatment. The development of Australia's first take-home naloxone program in the ACT has been an 'icebreaker' for the development of other Australian programs. If take-home naloxone programs continue to be shown to be safe and contribute to overdose reversals in this country, a scaling up to a level where macro, population level impacts on overdose rates can be determined is warranted.
